Researchers probing genes, drugs, brain scans to find better anxiety treatmentsApril 19th, 2008 - 12:55 pm ICT by admin
Washington , Apr 19 (ANI): A University of Michigan Medical research team is exploring the link between brain activity, genetics and medication to find out better anxiety treatments for those who do not benefit much from medicines prescribed by the doctor.
K. Luan Phan, M.D., and his former colleagues at University of Chicago came out with intriguing findings from a brain imaging study in occasional, non-dependent, marijuana users.
The findings were made in a placebo-controlled design, after giving the volunteers delta-9-tetrahydrocannabinol (THC), the active ingredient in marijuana, and exposing them to photographs of emotional faces, which served as signals of social communication.
The results indicated that THC reduces the response to threat in a brain region called the amygdala, and this made the researchers to come down on an area of the brain that may act as a potential target for new anti-anxiety drugs.
In order to search for more clues as to how anxiety treatment could be tailored to the individual patient, to give the best chance that a treatment will work for him or her, Phan is set to conduct a new clinical trial, which is currently seeking participants.
This new study will involve testing a generic form of the drug Zoloft (sertraline), a selective serotonin reuptake inhibitor (SSRI) approved by the U.S. Food and Drug Administration for social anxiety disorder and other anxiety disorders. Both people with social anxiety disorder and a comparison group of people without anxiety are needed for brain scanning and genetic testing.
The main purpose behind this study is to see if variations in the genes for certain brain receptors and transporters are linked with variations in how a persons brain reacts to pictures of emotional faces, and variations in how they respond to the anti-anxiety drug.
And this would ultimately guide the researchers towards an individualized or personalized approach to medical care.
These two studies are trying to get to the same goal: to find better treatments for anxiety disorders that affect millions of Americans and seriously interfere with their functioning, says Phan, an assistant professor of psychiatry at U-M and the VA Ann Arbor Healthcare System.
The cannabis study highlights a new avenue that we need to explore further as we try to develop novel medications, while the sertraline study will try to find out if we can tell which patients might or might not respond well, and by what mechanism, to an already existing medication known to have some efficacy in treating anxiety disorders, he added.
The study was published last month in the Journal of Neuroscience. (ANI)
- Brain's 'fear' area doesn't increase anxiety but counters it: Study - Mar 10, 2011
- How Prozac alters brain plasticity - Mar 16, 2011
- New target for antidepressants revealed - Jun 01, 2010
- Key ingredient makes marijuana cause memory loss - Oct 05, 2010
- Ecstasy could help ease trauma long term - Apr 17, 2010
- Common antidepressant drugs linked to delayed lactation - Jan 27, 2010
- Prescription marijuana without memory loss on horizon - Mar 03, 2012
- Cannabis ingredient 'can boost cancer patients' appetites, sense of taste' - Feb 23, 2011
- New mechanism controls efficacy of marijuana-like substance in brain - Aug 07, 2010
- Mood, anxiety disorders patients likely to abuse painkillers - Dec 14, 2011
- Antidepressants could alter personality while relieving symptoms - Dec 08, 2009
- Marijuana use could lead to sexual dysfunction in men - Feb 12, 2011
- Switching medications, regular therapy could help teens with severe depression - May 18, 2010
- Key ingredient dilutes marijuana's effect on memory - Oct 02, 2010
- Pot Smoking Shown to Relieve Chronic Pain Relief - Sep 01, 2010
Tags: active ingredient in marijuana, anxiety disorders, anxiety treatment, anxiety treatments, brain activity, brain imaging, brain receptors, brain region, comparison group, delta 9, food and drug administration, marijuana users, medical research team, michigan medical, selective serotonin reuptake inhibitor, serotonin reuptake inhibitor, social anxiety disorder, social communication, target, tetrahydrocannabinol thc